Table 2.
Pharmacokinetic and pharmacodynamic structural model parameter estimates for the effect of nicorandil on PAWP using model 10. Bootstrap coefficient of variation (standard deviation/median) and empirical 90% confidence interval
| Statistic | Description | Median | Units | CV % | Confidence interval | |
|---|---|---|---|---|---|---|
| 5% | 95% | |||||
| POP_S0 | Baseline PAWP | 25.6 | mmHg | 2.7 | 24.6 | 26.8 |
| POP_Sss | Steady state PAWP | 19.5 | mmHg | 10.0 | 16.5 | 22.7 |
| POP_TPROG | Progress half-life | 5.83 | h | 69.4 | 0.920 | 11.9 |
| POP_Emax | Maximum effect of nicorandil on PAWP | −11.7 | mmHg | 58.7 | −30.0 | −7.48 |
| POP_EC50 | Nicorandil concentration at 50% of Emax | 423 | µg l−1 | 107.1 | 165 | 1552 |
| POP_CL | Nicorandil clearance | 26.3 | l h−1 70 kg−1 | 13.5 | 21.9 | 31.5 |
| POP_V1 | Central volume of distribution | 18.1 | l 70 kg−1 | 14.8 | 14.9 | 23.3 |
| POP_Q | Intercompartmental clearance | 71.6 | l h−1 70 kg−1 | 76.9 | 54.5 | 203 |
| POP_V2 | Peripheral volume of distribution | 24.1 | l 70 kg−1 | 6.6 | 21.1 | 25.4 |
| FCL | Fractional CL change in heart failure | 1.94 | 25.0 | 1.03 | 2.63 | |
| FV1 | Fractional V1 change in heart failure | 1.39 | 17.0 | 1.05 | 1.81 | |
| FQ | Fractional Q change in heart failure | 0.519 | 42.8 | 0.192 | 0.891 | |
| FV2 | Fractional V2 change in heart failure | 4.06 | 219.1 | 1.83 | 25.3 | |